EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Toward In Vivo CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design

Ludovica Sciuto, Sander A A Kooijmans, Raymond M Schiffelers iD

Nano Letters · 25.02.2026 · 26 (7) · 2337-2347

DOI: 10.1021/acs.nanolett.5c05535 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nano Letters, online erschienen am 11.02.2026. Verfasst von Ludovica Sciuto und 2 weiteren Autor:innen. Beteiligte Einrichtung: CDL Research, Division LAB, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Nanoparticles, Lipids, T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Holland Top Consortia for Knowledge and Innovation program, European Research Council, HORIZON EUROPE European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CAR T cell therapy represents a leading therapeutic modality in the treatment of hematological cancers. However, conventional ex vivo manufacturing processes are extremely complex, costly, and time-consuming. Hence, in vivo CAR-T cell therapy represents a promising alternative, where T cells are genetically modified directly within the patient. This novel approach requires the careful design of three modular and interdependent nanoscale parameters: CAR architecture, targeted lipid nanoparticle delivery systems, and nucleic acid cargo format. Each component is highly modular, therefore systematic optimization can enhance the safety and efficacy of in vivo CAR T cell generation. Here, we review the molecular and mechanistic principles underlying this therapeutic strategy, emphasizing how these nanoscale design features govern CAR T cell production and functional performance in vivo. Advancing our understanding of these parameters is critical to developing efficient, safe, and clinically translatable in vivo CAR T cell cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesLipidsT-LymphocytesImmunotherapy, AdoptiveReceptors, Chimeric AntigenNeoplasmsHumansAnimalsLiposomes

Stichwörter der Autor:innen

CAR T cellsdrug targetinglipid nanoparticlesnanomedicinenucleic acid therapeutics

Substanzen

LipidsReceptors, Chimeric AntigenLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • CDL Research, Division LAB, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
  • Metabolic Diseases Research, Wilhelmina Children's Hospital, University Medical Center Utrecht, Lundlaan 6, 3584 EA Utrecht, The Netherlands.
  • Regenerative Medicine Center Utrecht, Uppsalalaan 8, 3584 EA Utrecht, The Netherlands.
  • Nanocell Therapeutics BV, Yalelaan 62, 3584 CM Utrecht, The Netherlands.

ORCID-Profile: Raymond M Schiffelers

Förderung

  • Health Holland Top Consortia for Knowledge and Innovation program
  • European Research Council
  • HORIZON EUROPE European Research Council
  • Health~Holland

Zitieren

APA

Sciuto, L., Kooijmans, S. A. A., & Schiffelers, R. M. (2026). Toward In Vivo CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design. Nano Letters, 26(7), 2337-2347. https://doi.org/10.1021/acs.nanolett.5c05535

Vancouver

Sciuto L, Kooijmans SAA, Schiffelers RM. Toward In Vivo CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design. Nano Letters. 2026;26(7):2337-2347. doi:10.1021/acs.nanolett.5c05535

BibTeX
@article{Sciuto2026,
  author = {Sciuto, Ludovica and Kooijmans, Sander A A and Schiffelers, Raymond M},
  title = {Toward In Vivo CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design},
  journal = {Nano Letters},
  year = {2026},
  volume = {26},
  number = {7},
  pages = {2337--2347},
  doi = {10.1021/acs.nanolett.5c05535}
}
Kostenlos starten →